scispace - formally typeset
Journal ArticleDOI

The interferon signature in autoimmune diseases.

Lars Rönnblom, +1 more
- 01 Mar 2013 - 
- Vol. 25, Iss: 2, pp 248-253
Reads0
Chats0
TLDR
The observed IFN signature in several autoimmune diseases is a biomarker of active disease and is investigated as a tool when selecting treatment for individual patients.
Abstract
Purpose of reviewAn increased expression of type I interferon (IFN) regulated genes (an IFN signature) has been reported in blood and tissue cells from patients with SLE and other autoimmune diseases. We review the possible mechanisms behind the IFN signature as well as clinical and therapeutic cons

read more

Citations
More filters
Journal ArticleDOI

Type I IFN Contributes to the Phenotype of Unc93b1D34A/D34A Mice by Regulating TLR7 Expression in B Cells and Dendritic Cells.

TL;DR: The roles of inflammatory cytokines such as IFN-γ, IL-17A, and type I IFNs are examined to understand the mechanism underlying the phenotype in D34A mice and it is suggested that these TLR7-expressing cells are activated initially and influence TLR 7-dependent systemic inflammation.
Journal ArticleDOI

Sjögren’s syndrome, should we sign?

TL;DR: Type I interferons (IFNs) play a significant role in the pathogenesis of primary Sjögren’s syndrome (pSS) and may contribute to overactivation of the innate and adaptive immune system, finally leading to B-cell hyperactivity, autoimmunity, and dysfunctioning of the glandular tissue.
Dissertation

Clinical and molecular characterization of the type I interferon signature in rheumatic diseases

T.D. de Jong
TL;DR: The cover of this thesis symbolizes heterogeneity in rheumatoid arthritis: although all patients have swollen joints by definition, there are many interindividual differences, such as presence and absence of a type I IFN signature, and plenty other aspects that need much more PhD theses to be fully addressed.
Journal ArticleDOI

Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus

TL;DR: The therapeutic potential of Jak kinases in light of the cytokine network that JAK kinases are able to interact with is discussed and the theoretical background for the rationale of blocking cytokines with specific JAK inhibitors is provided.
Journal ArticleDOI

A cluster of type II interferon-regulated genes associates with disease activity in patients with systemic lupus erythematosus.

TL;DR: In this article , the authors determined an IFN signature based on the expression of 128 interferon-regulated genes (IRGs) in whole blood from 34 systemic lupus erythematosus (SLE) patients in a cross-sectional (CS) study.
References
More filters
Journal ArticleDOI

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

TL;DR: Global gene expression profiling of peripheral blood mononuclear cells is used to identify distinct patterns of gene expression that distinguish most SLE patients from healthy controls, and identify a subgroup of patients who may benefit from therapies targeting the IFN pathway.
Journal ArticleDOI

Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood

TL;DR: Microarray analysis of blood cells reveals that immature granulocytes may be involved in SLE pathogenesis, and the IFN signature confirms the central role of this cytokine in Sle, using oligonucleotide microarrays.
Journal ArticleDOI

JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease

TL;DR: Not only have genome-wide association studies demonstrated that this pathway is highly relevant to human autoimmunity, but targeting JAKs is now a reality in immune-mediated disease.
Related Papers (5)